Invatec targets atherosclerosis below the knee with drug-eluting balloon
Invatec, a provider of interventional products, has launched its new peripheral balloon, the In.Pact Amphirion paclitaxel-eluting PTA balloon catheter, in Europe.
The Leipzig, Germany-based company said its drug-eluting catheter is designed to treat atherosclerosis in arteries located below the knee, and features a coating that frees and separates paclitaxel molecules and facilitates absorption into the wall of the artery.
The FreePac coating was developed in close collaboration with Ulrich Speck, PhD, from the department of radiology at Chariteï Mitte in Berlin and Bruno Scheller, MD, from the department of internal medicine at University Hospital in Homburg/Saar, Germany.
Invatec said it plans to launch a randomized trial—the In.Pact Deep study—in the first half of 2009, to provide additional data about the effectiveness of this new treatment concept.
The Leipzig, Germany-based company said its drug-eluting catheter is designed to treat atherosclerosis in arteries located below the knee, and features a coating that frees and separates paclitaxel molecules and facilitates absorption into the wall of the artery.
The FreePac coating was developed in close collaboration with Ulrich Speck, PhD, from the department of radiology at Chariteï Mitte in Berlin and Bruno Scheller, MD, from the department of internal medicine at University Hospital in Homburg/Saar, Germany.
Invatec said it plans to launch a randomized trial—the In.Pact Deep study—in the first half of 2009, to provide additional data about the effectiveness of this new treatment concept.